NTLA Intellia Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NTLA

Price (delayed)

$11.83

Market cap

$1.66B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.35

Enterprise value

$1.62B

?
Relative Growth: Rel. Growth: 37
Relative Strength: Rel. Strength: 39
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 35

Intellia Therapeutics, Inc. is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop ...

Highlights
The company's debt fell by 28% YoY and by 9% QoQ
The EPS has grown by 28% YoY and by 5% from the previous quarter
The gross profit has grown by 13% YoY but it has contracted by 10% from the previous quarter
Intellia Therapeutics's revenue has increased by 13% YoY but it has decreased by 10% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.intelliatx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of NTLA

NTLA stock price

How has the Intellia Therapeutics stock price performed over time
Intraday
-2.15%
1 week
5.25%
1 month
-9.14%
1 year
7.55%
YTD
31.59%
QTD
-30.08%

Financial performance

How have Intellia Therapeutics's revenue and profit performed over time
Revenue
$59.51M
Gross profit
$59.51M
Operating income
-$423.48M
Net income
-$399.98M
Gross margin
100%
Net margin
-672.2%
Intellia Therapeutics's operating margin has increased by 27% YoY but it has decreased by 12% QoQ
The company's net margin rose by 26% YoY but it fell by 13% QoQ
The net income has grown by 17% YoY
The company's operating income rose by 17% YoY

Price vs fundamentals

How does NTLA's price correlate with its fundamentals

Growth

What is Intellia Therapeutics's growth rate over time

Valuation

What is Intellia Therapeutics stock price valuation
P/E
N/A
P/B
2.27
P/S
26.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.31
The EPS has grown by 28% YoY and by 5% from the previous quarter
The stock's P/B is 31% below its 5-year quarterly average of 3.3 and 5% below its last 4 quarters average of 2.4
Intellia Therapeutics's equity has increased by 17% from the previous quarter
The price to sales (P/S) is 66% lower than the 5-year quarterly average of 77.6 and 2.1% lower than the last 4 quarters average of 27.1
Intellia Therapeutics's revenue has increased by 13% YoY but it has decreased by 10% QoQ

Efficiency

How efficient is Intellia Therapeutics business performance
The ROS has grown by 26% YoY but it has contracted by 13% from the previous quarter
Intellia Therapeutics's ROIC has decreased by 13% YoY
The ROA has contracted by 4.6% YoY and by 2.6% from the previous quarter

Dividends

What is NTLA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NTLA.

Financial health

How did Intellia Therapeutics financials performed over time
Intellia Therapeutics's total liabilities has decreased by 30% YoY and by 6% QoQ
NTLA's current ratio is up by 28% year-on-year and by 9% since the previous quarter
The company's debt is 90% lower than its equity
The debt to equity has contracted by 29% YoY and by 23% from the previous quarter
The company's debt fell by 28% YoY and by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.